Home
About +
Our Story
Meet the Team
FAQs
Our Science +
Inhaled IFN-β
Clinical Trials
Publications
Investors +
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Investor Calendar
News +
Press Releases
Resources
Factsheets
TR-1/Options Press Releases
Careers
Contact
Home
About
Our Science
Investors
News
Careers
Contact
Back
Our Story
Meet the Team
FAQs
Back
Inhaled IFN-β
Clinical Trials
Publications
Back
Share Price Information
Reports & Presentations
Investor News
Shareholder Information
AIM Rule 26
Corporate Governance
Investor Calendar
Back
Press Releases
Resources
Factsheets
TR-1/Options Press Releases
Media
Read our latest news and download information and resources.
Featured News
Grant of Options
Appointment of Joseph Colliver as New Chief Financial Officer
Synairgen appoints Dr Marcin Mankowski as Chief Medical Officer
In the News
Discover all mentions
Read our CEO Richard Marsden's 2023 Letter
The Need - and Opportunity - to Develop Broad-Spectrum Antivirals by Dr Phillip Monk
ITN Lungs Matter
Press
View all press releases
Subscribe to news
2023
Grant of Options
15th November 2023
Appointment of Joseph Colliver as New Chief Financial Officer
11th October 2023
Synairgen appoints Dr Marcin Mankowski as Chief Medical Officer
3rd October 2023
Interim Results
21st September 2023
Result of AGM
29th June 2023
Annual General Meeting Presentation
29th June 2023
Posting of Annual Report and Notice of 2023 AGM
23rd May 2023
Results for the year ended 31 December 2022
27th April 2023
Notice of Full Year results
17th April 2023
2022
SPRINTER Trial Results Published
23rd December 2022